SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership to scale production of its Intelligent Fingerprinting Drug Screening Reader, ahead of its anticipated U.S. market entry and promising significant operational benefits. The community is actively debating its low float and short squeeze potential, with many discussing whether recent price action is a "stop raid" for further upside or a sign of an impending offering.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to its volatile price action as a low-float SPAC, prompting intense community discussion around its potential for a short squeeze or significant gains. Traders are closely watching its 'tiny float' and high insider ownership, drawing parallels to other recent 'shell company rippers' amidst sharp price swings and trading halts. This speculative interest sees many buying dips and holding, anticipating further explosive moves.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing extreme volatility, driven by recent CME margin requirement hikes that many in the community view as manipulation to suppress prices. Amid swirling rumors of Chinese export restrictions on silver, traders are sharply divided between anticipating a massive short squeeze from strong physical demand and expecting a significant pullback in the paper market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is a hot topic, drawing mixed community sentiment regarding its future performance, with many anticipating significant appreciation while others note recent stagnation. Discussions frequently revolve around its foundational role as "digital silver" and the potential for technical indicators to signal a major upward movement. The community is also closely watching broader crypto market trends and Grayscale's influence on LTC's trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following a recent FDA approval of NEREUS, its motion-sickness treatment, marking the first new pharmacologic option in decades. The community is actively discussing the drug's potential expansion into the multi-billion dollar GLP-1 nausea market and views VNDA as a prime takeover target, anticipating further catalysts from its robust pipeline including a February FDA decision for Bysanti.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is currently trending on the Cardano ecosystem as its passionate community, known as the "flock," enthusiastically highlights the token's real-world utility through its CockyWingsLLC fried chicken food truck business and a new MemesHub.io DApp. This meme coin is generating buzz for bringing liquidity on-chain and offering passive income opportunities through its liquid staking "Arena," with many anticipating significant growth into 2026.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is a hot topic as it undergoes a significant corporate restructuring, including discontinuing its lead drug and exploring strategic alternatives like a sale or merger. The immediate catalyst for community conversation is its exceptionally low share float, which is fueling intense speculation about a potential short squeeze. Traders are actively comparing $SNSE to recent parabolic runners, with many anticipating substantial upward momentum despite the company's fundamental changes.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is experiencing renewed interest due to significant institutional developments, including PayPal's stablecoin integration, U.S. Bank's testing of custom stablecoins, and its inclusion in Franklin Templeton's crypto ETF, alongside upcoming network upgrades like Protocol 25. While a segment of the community expresses strong bearish sentiment regarding current price action, others are actively accumulating, bullish on its long-term potential as an ISO 20022 compliant asset. This divergence reflects a battle between immediate price concerns and optimism for XLM's role in the evolving landscape of institutional and cross-border finance.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is highly volatile after the FDA issued a Complete Response Letter for its relacorilant application, seeking additional efficacy evidence despite positive Phase 3 trial data. The market's sharp sell-off is widely viewed by the community as an overreaction, given the company's substantial existing revenue from Korlym, strong cash reserves, and other promising pipeline assets. Investors are now debating the likelihood of a narrower resubmission for relacorilant and the potential for a significant rebound, with many eyeing a temporary bottom.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA has granted priority review to its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, pointing to an accelerated review timeline. This pivotal development, coupled with strong Auvelity sales and anticipated progress toward an NDA for AXS-12 in narcolepsy, is fueling widespread investor optimism. The community is actively discussing Axsome's "best-in-class" pipeline and commercial execution, anticipating significant long-term value appreciation within the CNS therapeutic landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Healthcare ETF (IYH) Hits New 52-Week High

IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.

<ul class="summary-bullets"><li>Prasad, who oversees gene therapies in the FDA, told Bloomberg that regulation needs to evolve as science develops.</li><li>The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. &nbsp;</li></ul>A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug Administration, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments">told</a> Bloomberg that regulation needs to evolve as science develops. Prasad reportedly added that scientific advances like Nobel prize-winning CRISPR gene-editing technology have forced the agency to relax some of its strict rules.The agency is “going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it,” Prasad told Bloomberg.The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. Prasad expects it will spark interest in developing treatment for rare diseases.<h2 class="st-heading-2">CRISPR’s Potential</h2>CRISPR gene editing is a technology that allows scientists to modify an organism's DNA precisely. It involves a guide RNA that directs a DNA-cutting enzyme to a specific target in the DNA for it to make a cut. The cell's natural repair process either inactivates the gene or allows scientists to insert a new piece of DNA.Earlier this year, an infant named KJ Muldoon, born with a rare genetic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, was successfully treated with a customized CRISPR gene editing therapy by a team at the Children’s Hospital of Philadelphia.The team behind the treatment of the infant is now designing clinical trials that can be used to gain FDA approval with a gene-editing platform that can be tailored for patients with different genetic mutations, Bloomberg reported. The team is asking for FDA permission to start clinical trials for a liver disorder known as phenylketonuria and urea cycle disorders, the report added.These diseases can be treated by editing genes in the liver, a known target for CRISPR, team members told Bloomberg.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-shares-soar-premarket-as-ceo-sees-continued-demand-for-blockbuster-drug-ibsrela/cLGqRUcR3Ur">Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 

Equity

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 


UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


President Donald Trump on Monday called on the Democrats to end the government shutdown, which is now in its sixth day, while also expressing his willingness to negotiate with them on healthcare, the key sticking point.In a Truth Social post, Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115329671584864920">said</a>, “Democrats have SHUT DOWN the United States Government right in the midst of one of the most successful Economies, including a Record Stock Market, that our Country has ever had.” The president lamented that this has affected several programs, services and other things the Americans rely on, adding that “It should not have happened.After the Republicans and Democrats could not agree on a stopgap funding deal, the government has been shut down since the start of the fiscal year (October 1). In a report released last Wednesday, Morgan Stanley strategists stated that the possibility of permanent layoffs among federal workers, as well as delays in economic reports, could make the first shutdown in six years more consequential than previous instances.Notwithstanding the headwind, the stock market has been on a tear, clocking fresh highs in a trot. On Monday, all the major stock market gauges closed at fresh records, thanks to the boost provided by artificial intelligence (AI) news flow.For the year-to-date (YTD) period, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> have gained 15.6% and 19.3%, respectively. On Stocktwits, retail traders remained cautious, with the sentiment toward both the SPY and QQQ ETF remaining ‘bearish’ by late Monday. The message volume on the SPY stream remained ‘high,’ while that on the QQQ was at ‘normal’ levels.&nbsp;In his post, Trump said, “I am happy to work with the Democrats on their Failed Healthcare Policies, or anything else, but first they must allow our Government to reopen. In fact, they should open our Government tonight!”The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire. The expiration of healthcare funding would result in a sharp spike in the healthcare premiums Americans pay. Meanwhile, the Republicans want a plan to keep the government funded until Nov. 21 and negotiate spending policy only through the regular funding process.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a>, which is up about 5.4% YTD, attracted ‘neutral’ sentiment, a deterioration from the ‘bullish’ mood seen the day before, but the message volume stayed ‘high.’Earlier in the day, while talking to reporters in the Oval Office, Trump said, “We have a negotiation going on right now with the Democrats that could lead to very good things. And I’m talking about good things with regard to health care, the Hill <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://thehill.com/policy/healthcare/5541610-trump-democrats-healthcare-deal/">reported.</a> When asked if the Affordable Care Act (ACA), aka Obamacare Act, subsidies would be extended, the president said, “If we made the right deal, I’d make a deal. Sure.”“You have subsidies, that’s the problem with ObamaCare. The subsidies are so much, it’s billions and billions of dollars is being wasted. And we could have a much better health care than we have right now. And we’re talking to them. I’m not saying that’s going to happen.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-vouches-for-microsoft-cloud-growth-with-675-price-target/ch6RQDgR3gw">Wells Fargo Vouches For Microsoft Cloud Growth With $675 Price Target On Stock</a>

U.S. President Donald Trump speaks in the Oval Office at the White House on October 06, 2025 in Washington, DC. 

Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown 

The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire.

The looming&nbsp;U.S. government shutdown is seen as a significant headline risk for the market, which has been on an extended bull run. An absence of a deal&nbsp;regarding government funding among lawmakers by Sept. 30, when the fiscal year ends, could result in massive layoffs, further complicating the economic outlook.The standoff concerns a plan for discretionary funding for the upcoming fiscal year. On Sept. 19, a stopgap bill to fund the government through Nov. 21 failed to clear the Senate, where it needed 60 votes, after the Republican-controlled House passed it.An ongoing Stocktwits poll,&nbsp;in partnership with Polymarket, which asked platform users if the U.S. government would shut down this year, found that opinions were split equally. While 51% of the respondents said it&nbsp;was unlikely, 48% said it&nbsp;was likely to occur.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_12_08_AM_png_a52535d339.webp" alt="Screenshot 2025-09-29 at 2.12.08 AM.png">According to Polymarket, Stocktwits’ predictions market partner, the odds of a government shutdown have decreased to 72% from 80% as of Friday. The improved odds reflected optimism after reports, citing a White House official,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-meet-top-congressional-leaders-monday-white-house-official-says-2025-09-28/">stated</a> that President Donald Trump would meet with top lawmakers from both sides of the aisle on Monday to discuss government funding and avert a shutdown. Incidentally, the president cancelled a previous meeting with Rep. Hakeem Jeffries (D-N.Y.) and Sen. Chuck Schumer (D-N.Y.) to discuss the issue.&nbsp;The main area of contention is the Affordable Care Act tax credit subsidies, which are set to expire by the end of the year. While Democrats are fixated on discussing an extension as part of the negotiations, their Republican counterparts believe there is still time to address the issue.In his preview of the week ahead, economist Mohamed El-Erian said, “All eyes will be on Washington as the U.S. Congress attempts to iterate toward an agreement to avoid a government shutdown,”&nbsp;adding that&nbsp;much depends on the ongoing negotiations between the Trump Administration and Congressional leaders.In a joint statement, Democratic leaders Jefferies and Schumer confirmed Monday’s meeting with Trump and expressed their willingness to help resolve the crisis. “We are resolute in our determination to avoid a government shutdown and address the Republican healthcare crisis,” they said.The stock market has been chugging along nicely despite the multiple headwinds the economy is facing. The major indices trade just shy of their records, with the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> having risen 14% and 17%, respectively, year-to-date.On Stocktwits, sentiment toward both ETFs was ‘neutral’ as of early Monday, while the message volume on both streams remained at ‘high’ levels. The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a> is down 1% this year.&nbsp;Economists and market participants are mainly worried about the shutdown as investors close out the month and quarter, according to a MarketWatch <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/the-last-thing-the-stock-market-wants-right-now-is-a-government-shutdown-heres-why-7bac216e?mod=home_lead">report.</a> Charles Schwab investment strategist Kevin Gordon reportedly said, “This one could come at a really unfortunate time because we are supposed to get the jobs report on Friday,” adding that “If we don’t get access to that data, it’s going to be a problem.”The report also stated that Wells Fargo Global Strategist Gary Schlossberg said, “At the moment, we view the government shutdown on Oct. 1 as a high-probability event, likely lasting long enough to delay release of the September jobs [report] and, likely, CPI releases, due out October 3 and 15, respectively.”He sees any shutdown now as causing more extensive disruptions to data releases than the partial shutdown that occurred between December 2018 and January 2019 because more agencies are poised to be impacted by the lack of appropriation bills passed by Congress.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-s-paul-atkins-signals-fast-track-for-trump-plan-not-retreat-from-transparency/chDMru6R37X">Goodbye Quarterly Earnings? SEC’s Paul Atkins Signals Fast-Track For Trump Plan But Says It’s ‘Not A Retreat From Transparency’</a>

Tourists walk through the Rotunda in the U.S. Capitol Building on September 23, 2025 in Washington, DC. 

Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.

US Government Shutdown Risk Splits Retail Traders — Strategists Warn Key Jobs Report Could Be Delayed

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.


A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

IYH
iShares US Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYH News

IYHiShares US Healthcare ETF